Accession Number: | 0001104659-20-042771 |
Date: | 2020-04-02 |
Issuer: | RA PHARMACEUTICALS, INC. (RARX) |
Original Submission Date: |
RICARDO ALONSO
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-04-02 | D | 2,973 | d | $48.00 | 0 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION (RIGHT TO BUY) | 0.84 | 2020-04-02 | deemed execution date | D | 2,857 (d) | 2022-06-14 | common stock 2,857 | $0.84 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.87 | 2020-04-02 | deemed execution date | D | 14,285 (d) | 2024-12-11 | common stock 14,285 | $2.87 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 2.87 | 2020-04-02 | deemed execution date | D | 30,000 (d) | 2025-12-10 | common stock 30,000 | $2.87 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 5.6 | 2020-04-02 | deemed execution date | D | 31,428 (d) | 2026-08-16 | common stock 31,428 | $5.60 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 16.64 | 2020-04-02 | deemed execution date | D | 60,000 (d) | 2027-02-01 | common stock 60,000 | $16.64 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 7.33 | 2020-04-02 | deemed execution date | D | 26,250 (d) | 2028-02-01 | common stock 26,250 | $7.33 | 0 | direct | ||
STOCK OPTION (RIGHT TO BUY) | 21.0 | 2020-04-02 | deemed execution date | D | 107,000 (d) | 2029-02-01 | common stock 107,000 | $21.00 | 0 | direct | ||
RESTRICTED STOCK UNITS | 0.0 | 2020-04-02 | deemed execution date | D | 4,375 (d) | common stock 4,375 | $0.00 | 0 | direct |
ID | footnote |
---|---|
f1 | includes 2,973 shares of issuer common stock acquired upon the vesting and net settlement of restricted stock units on february 1, 2020. |
f2 | disposed of pursuant to an agreement and plan of merger (the "merger agreement"), dated october 9, 2019, among ra pharmaceuticals, inc. (the "issuer"), ucb s.a., and franq merger sub, inc., providing for the merger (the "merger") of franq merger sub, inc. into the issuer, in exchange for a cash payment of $48.00 per share. |
f3 | pursuant to the merger agreement, at the effective time of the merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option. |
f4 | pursuant to the merger agreement, at the effective time of the merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit. |